Is compounded semaglutide safe?

What "compounded" means and who regulates it

Compounding is the process of preparing a customized medication for an individual patient, at a dose, formulation, or concentration not available in a commercially manufactured product. Two federal categories govern this practice in the United States, and understanding them is the foundation of any honest safety discussion.

503A state-licensed pharmacies compound medications based on individual patient prescriptions. They are regulated primarily by their state board of pharmacy and are not required to register with the FDA. They must follow state standards and federal law, including requirements for sterile compounding.

503B outsourcing facilities are larger operations that have registered with the FDA and are held to Current Good Manufacturing Practice (CGMP) standards, similar to those applied to pharmaceutical manufacturers. FDA registration means these facilities are subject to federal inspections. It does not mean their products are FDA-approved.

Neither category produces FDA-approved medications. The FDA does not evaluate any compounded drug for safety, efficacy, or quality before it is dispensed, regardless of where it is made. This is not a technicality: it is the defining regulatory difference between compounded products and drugs that carry full FDA approval. According to a 2025 analysis published in the Journal of the Endocrine Society, compounded GLP-1 formulations "lack rigorous testing for how they're absorbed, distributed, and eliminated compared to FDA-approved formulations."

Why compounded GLP-1s became widespread from 2022 to 2025

Compounded semaglutide did not appear from nowhere. It was a direct response to a years-long supply shortage driven by demand that outpaced manufacturing capacity. According to the FDA's declaratory order on the semaglutide shortage, prescription fills for semaglutide rose 442 percent between January 2021 and December 2023.

The FDA added Wegovy (semaglutide 2.4 mg, approved for chronic weight management) to its Drug Shortage List in March 2022, and Ozempic (semaglutide for type 2 diabetes management) in August 2022. Under federal law, when a drug is on the active shortage list, compounding pharmacies may prepare that drug to meet patient needs the commercial supply cannot fulfill. That provision is what made compounded semaglutide legally available for roughly three years.

On February 21, 2025, the FDA declared the semaglutide shortage resolved, confirming that Novo Nordisk had sufficient supply and manufacturing capacity to meet national demand. That declaration effectively closed the primary legal basis for large-scale compounding. The FDA gave 503A pharmacies a deadline of April 22, 2025, and 503B outsourcing facilities a deadline of May 22, 2025, to stop bulk compounding of semaglutide.

In April 2026, the FDA went further, proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, a step that, if finalized, would permanently close the large-scale outsourcing pathway for these drugs.

What FDA approval covers, and why compounded drugs are different

FDA approval for a drug means the agency has reviewed a specific manufacturer's submitted data on safety, efficacy, and manufacturing quality for that exact product. FDA-approved semaglutide products (Ozempic, Wegovy, and Rybelsus) carry that review. Their formulations, potency, sterility standards, and labeling have all been evaluated before reaching patients.

Compounded semaglutide has not undergone that process for any formulation prepared by any compounding pharmacy. Each pharmacy's product is, in practice, a distinct preparation. Without pre-market FDA review, the responsibility for quality verification rests with the pharmacy, the prescribing clinician, and to some extent the patient, rather than with a federal regulatory agency.

A compounded drug is also not a generic. A generic drug is required to demonstrate bioequivalence to an approved product through regulated clinical testing. Compounded drugs do not undergo that testing and cannot legally be marketed as generics, equivalents, or substitutes for named brand products. The FDA has specifically prohibited this language and has issued multiple waves of warning letters to companies using equivalence phrasing in marketing materials.

Being clear about these distinctions is not the same as saying compounded products are inherently dangerous. A well-run, accredited compounding pharmacy can produce sterile, correctly dosed injectable medications. The difference is in where the quality assurance responsibility sits and what evidence a patient can request to verify it.

What the FDA's adverse event data actually shows

Adverse event data provides the clearest picture of documented real-world harms. As of November 30, 2024, the FDA had received 392 adverse event reports associated with compounded semaglutide and 215 reports for compounded tirzepatide, according to the Journal of the Endocrine Society analysis. By April 30, 2025, those numbers had risen to 520 reports for compounded semaglutide and 480 for compounded tirzepatide, per the University of Illinois Chicago Drug Information Group.

These numbers likely underrepresent actual events, because 503A state-licensed pharmacies are not required to report adverse events directly to the FDA. Reported adverse effects included severe nausea, vomiting, dehydration, fainting, pancreatitis, and gallstones requiring hospitalization.

Three distinct categories explain the documented adverse events. Understanding each one helps separate risks that come with compounding itself from risks that come from operating outside the legitimate compounding system.

• Dosing errors: The most common cause, traceable to multi-dose vials requiring manual syringe measurement by patients unfamiliar with injectables
• Counterfeit and unlicensed products: Products falsely labeled or containing unknown ingredients, sold without prescriptions through unverified channels
• Unapproved salt forms: Formulations using semaglutide sodium or semaglutide acetate rather than the FDA-approved base form of the molecule

Dosing errors, the most common and most preventable risk

In July 2024, the FDA issued a specific alert after receiving multiple reports of patients administering five to twenty times their intended dose of compounded semaglutide. The consistent error pattern was confusion between milligrams, milliliters, and "units" when drawing medication from a multi-dose vial into an insulin syringe, according to the FDA dosing alert.

FDA-approved semaglutide products such as Wegovy and Ozempic come in pre-filled, single-dose injection pens with the dose clearly indicated and no volume measurement required by the patient. Compounded semaglutide is typically dispensed in multi-dose vials at varying concentrations depending on the pharmacy. A patient unfamiliar with injectable medications, given a vial and syringe without adequate written and verbal instruction, faces a meaningful risk of incorrect dosing.

Healthcare providers have also made errors when converting between concentration units, resulting in patients receiving significantly higher doses than intended. Because semaglutide has a half-life of approximately one week, an overdose cannot be quickly reversed and may require prolonged medical monitoring.

This risk is real and documented, but it is also closely tied to the adequacy of the provider's instruction and follow-up process. A legitimate program provides clear written injection instructions, begins at the lowest dose tier, confirms patient understanding before dispensing, and offers a reachable clinical contact for dosing questions. The absence of these safeguards is itself a warning sign. For the full step-by-step process a well-run program should cover with you, see how to inject semaglutide at home.

Counterfeit products and unlicensed sellers, a separate threat

Distinct from the question of legitimate compounding pharmacies, a serious problem exists in the market for counterfeit and fraudulently labeled products that are entirely outside the verified supply chain. In April 2025, the FDA seized counterfeit Ozempic products in the United States that were found to contain the wrong active ingredients. Separately, the agency documented fraudulently labeled "compounded semaglutide" products whose labels named compounding pharmacies that do not exist.

A February 2025 public safety advisory from the Internet Crime Complaint Center (IC3) warned that some sellers were marketing products claiming to contain semaglutide that actually contained unknown compounds, drug mixtures with high impurity levels, or no semaglutide at all. The IC3 advisory noted that products obtained from such sellers frequently contained unknown compounds, harmful impurities, or no semaglutide at all, and that purchases made without a valid prescription were the common factor in every documented case.

The common denominator across counterfeit cases is the absence of a prescription. Every documented case of fraudulent GLP-1 products involved direct sales through websites, social media accounts, or unlicensed operations that did not require a prescription or any legitimate prescriber involvement. A valid prescription from a licensed U.S. clinician, fulfilled by a named and verifiable pharmacy, is the clearest structural protection against counterfeit products.

Unapproved salt forms, a chemical distinction that matters

The FDA has flagged a formulation-specific concern that is separate from dosing and counterfeiting: the use of unapproved salt forms of semaglutide. The active ingredient in FDA-approved Ozempic, Wegovy, and Rybelsus uses the base (free acid) form of semaglutide. Some compounding pharmacies have used semaglutide sodium or semaglutide acetate as starting materials instead.

The FDA has stated that these salt forms "are not the same as the active ingredient" in the approved products and that their safety and effectiveness have not been evaluated, according to a DiaTribe review of FDA safety warnings. Whether this substitution meaningfully changes absorption, potency, or risk has not been established in published peer-reviewed trials. That absence of data is itself the concern.

A well-run compounding pharmacy will confirm in writing whether its formulation uses the base form of semaglutide. It should also provide, on request, a third-party certificate of analysis from a qualified laboratory confirming the identity, potency, purity, and sterility of the batch used to fill a patient's prescription. Asking for this documentation is a reasonable and appropriate step before starting any compounded injectable medication.

What major medical organizations have said

The American Diabetes Association issued a formal statement recommending against the use of non-FDA-approved compounded GLP-1 and dual GIP/GLP-1 receptor agonist products, citing safety and quality concerns, as noted in the Journal of the Endocrine Society analysis.

These recommendations reflect the population-level concern that, without standardized bioequivalence testing, quality control data, or pre-market FDA review, there is no reliable way for any physician to confirm in advance exactly how a given compounded product will behave in a given patient's body. Medical organizations advocating for patient safety tend toward conservative positions when a standardized, reviewed alternative is commercially available.

At the same time, clinical practice involves individual patients with specific circumstances. A licensed physician may conclude, for a specific patient who cannot access or afford FDA-approved products, that prescribing compounded semaglutide from a verified, accredited pharmacy under close clinical monitoring is an acceptable clinical decision. That determination belongs between the patient and their provider, based on a thorough evaluation of individual medical history and risk factors. Providers should never be skipped in this process.

How to evaluate a telehealth provider offering compounded semaglutide

Five concrete checks separate legitimate providers from the operations responsible for most of the documented risks described above.

Provider responsibility does not end at the prescription. A legitimate program monitors clinical response, adjusts dosing based on tolerance, and has a documented process for handling adverse effects. Ongoing clinical contact is both a quality signal and a safety requirement, not a luxury feature.

The regulatory picture in 2026

As of mid-2026, the regulatory environment for compounded semaglutide has narrowed significantly from the broad availability of 2022 to 2025. Large-scale 503B outsourcing facility compounding is no longer authorized under the shortage exemption, and the FDA's April 30, 2026 proposal, if finalized, would permanently close that pathway for semaglutide, tirzepatide, and liraglutide.

Individual patient-specific compounding by licensed 503A pharmacies may remain permissible under federal law when a prescribing clinician documents a specific clinical reason that no commercially available FDA-approved product can meet the patient's individual need. Acceptable documented justifications include a verified allergy to an inactive ingredient in the branded products, a required dose or concentration not commercially available, or a medically necessary formulation change. Cost alone does not meet this standard under current FDA compounding guidance.

Patients currently enrolled in a compounded semaglutide program should ask their provider specifically whether the prescription is based on documented individual clinical need and confirm the compounding pharmacy's current license status. This is a legitimate and appropriate question: a provider who cannot answer it clearly is a provider worth reconsidering. The regulatory landscape continues to evolve, and consulting a licensed healthcare provider remains the appropriate way to get current, personalized guidance.